MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - FRA:MED - DE0006595101 - Common Stock
3.5 EUR
+0.04 (+1.16%)
Taking everything into account, MED scores 6 out of 10 in our fundamental rating. MED was compared to 31 industry peers in the Health Care Providers & Services industry. While MED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. MED is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
MED had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MED's Return On Assets of 3.85% is fine compared to the rest of the industry. MED outperforms 70.97% of its industry peers.
MED's Return On Equity of 14.15% is fine compared to the rest of the industry. MED outperforms 74.19% of its industry peers.
MED has a better Return On Invested Capital (7.06%) than 67.74% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MED is below the industry average of 6.75%.
The last Return On Invested Capital (7.06%) for MED is above the 3 year average (3.46%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROIC | 7.06% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
MED's Profit Margin of 4.40% is fine compared to the rest of the industry. MED outperforms 74.19% of its industry peers.
MED's Profit Margin has improved in the last couple of years.
MED has a better Operating Margin (8.52%) than 70.97% of its industry peers.
In the last couple of years the Operating Margin of MED has grown nicely.
MED's Gross Margin of 84.08% is amongst the best of the industry. MED outperforms 80.65% of its industry peers.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MED is creating some value.
MED has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for MED remains at a similar level compared to 5 years ago.
MED has a better debt/assets ratio than last year.
2.2 Solvency
MED has an Altman-Z score of 1.58. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.58, MED is in line with its industry, outperforming 45.16% of the companies in the same industry.
MED has a debt to FCF ratio of 9.63. This is a negative value and a sign of low solvency as MED would need 9.63 years to pay back of all of its debts.
MED has a Debt to FCF ratio of 9.63. This is comparable to the rest of the industry: MED outperforms 54.84% of its industry peers.
A Debt/Equity ratio of 1.69 is on the high side and indicates that MED has dependencies on debt financing.
MED has a Debt to Equity ratio of 1.69. This is in the lower half of the industry: MED underperforms 64.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Altman-Z | 1.58 |
ROIC/WACC1.51
WACC4.68%
2.3 Liquidity
A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
MED's Current ratio of 1.93 is amongst the best of the industry. MED outperforms 87.10% of its industry peers.
A Quick Ratio of 1.89 indicates that MED should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.89, MED belongs to the best of the industry, outperforming 90.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 414.18%, which is quite impressive.
The Earnings Per Share has been growing by 20.79% on average over the past years. This is a very strong growth
MED shows a small growth in Revenue. In the last year, the Revenue has grown by 3.40%.
The Revenue has been growing slightly by 2.19% on average over the past years.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
3.2 Future
MED is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.85% yearly.
MED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.80% yearly.
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 4.73, the valuation of MED can be described as very cheap.
MED's Price/Earnings ratio is rather cheap when compared to the industry. MED is cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.89, MED is valued rather cheaply.
With a Price/Forward Earnings ratio of 6.48, the valuation of MED can be described as very cheap.
Based on the Price/Forward Earnings ratio, MED is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.59. MED is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.73 | ||
| Fwd PE | 6.48 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MED is valued cheaply inside the industry as 96.77% of the companies are valued more expensively.
MED's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MED is cheaper than 87.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.58 | ||
| EV/EBITDA | 2.8 |
4.3 Compensation for Growth
MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MED has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MED's earnings are expected to grow with 13.85% in the coming years.
PEG (NY)0.09
PEG (5Y)0.23
EPS Next 2Y14.23%
EPS Next 3Y13.85%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.16%, MED has a reasonable but not impressive dividend return.
MED's Dividend Yield is comparable with the industry average which is at 2.44.
Compared to an average S&P500 Dividend Yield of 2.44, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y14.23%
EPS Next 3Y13.85%
FRA:MED (11/14/2025, 7:00:00 PM)
3.5
+0.04 (+1.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.54%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap166.25M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts83.33
Price Target4.79 (36.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)26.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.73 | ||
| Fwd PE | 6.48 | ||
| P/S | 0.21 | ||
| P/FCF | 3.58 | ||
| P/OCF | 1.72 | ||
| P/B | 0.67 | ||
| P/tB | 0.74 | ||
| EV/EBITDA | 2.8 |
EPS(TTM)0.74
EY21.14%
EPS(NY)0.54
Fwd EY15.44%
FCF(TTM)0.98
FCFY27.97%
OCF(TTM)2.04
OCFY58.15%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.09
PEG (5Y)0.23
Graham Number9.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROCE | 9.1% | ||
| ROIC | 7.06% | ||
| ROICexc | 9.61% | ||
| ROICexgc | 10.05% | ||
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% | ||
| FCFM | 5.83% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Debt/EBITDA | 3.49 | ||
| Cap/Depr | 96.09% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | 3.18 | ||
| Cash Conversion | 80.47% | ||
| Profit Quality | 132.66% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z | 1.58 |
F-Score8
WACC4.68%
ROIC/WACC1.51
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
What is the valuation status for MED stock?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
What is the profitability of MED stock?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 4.73 and the Price/Book (PB) ratio is 0.67.
What is the earnings growth outlook for MEDICLIN AG?
The Earnings per Share (EPS) of MEDICLIN AG (MED.DE) is expected to grow by 52.44% in the next year.